Q-omics provides the consensus-scored MAGEB6B profile across patient tissues and cancer cell-line models. MAGEB6B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MAGEB6B is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, MAGEB6B RNA expression shows 4,948 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, LIHC, and TGCT as cancer lineages where MAGEB6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEB6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEB6B survival associations across molecular data types. MAGEB6B RNA expression shows survival associations in the most cancer types (13), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEB6B RNA expression–survival associations across cancer types. High MAGEB6B expression shows unfavorable associations in KIRP, PAAD, CESC, KIRC, READ and LIHC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MAGEB6B RNA expression.
This table summarizes MAGEB6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEB6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEB6B shows higher tumor expression in LIHC and LUSC. The LIHC box plot shows higher MAGEB6B RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .008).
This table shows molecular features associated with MAGEB6B in patient tissues and cancer cell lines. In patient samples, MAGEB6B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
